Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • CG-806 for B-cell Tumors
    • CG-806 for Myeloid Tumors
    • APTO-253
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • CG-806 for CLL & NHL
    • CG-806 for AML
    • APTO-253 for AML & MDS
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Careers
  • Contact

Press Releases

News

News

  • Press Releases
  • Presentations
  • Events

Aptose Biosciences Announces Results of Annual Meeting of Shareholders

Jun 05, 2018 4:05pm EDT

Aptose Announces Two Publications of Preclinical Data Elucidating the Anticancer Mechanism of Action of APTO-253

Jun 04, 2018 7:04am EDT

APTOSE Enters into US$20 Million Common Share Purchase Agreement with Aspire Capital Fund, LLC

May 31, 2018 7:04am EDT

Aptose to Present New CG’806 Data at the 23rd Congress of the European Hematology Association

May 17, 2018 11:43am EDT

Aptose Reports Results for the First Quarter Ended March 31, 2018

May 10, 2018 4:00pm EDT

Aptose Exercises Early Option for CG-806 License From CrystalGenomics

May 07, 2018 7:00am EDT

Aptose To Release First Quarter Ended March 31, 2018 Financial Results and Hold Conference Call on May 10, 2018

May 01, 2018 7:30am EDT

Aptose Announces Appointment of Caroline M. Loewy to Board of Directors

Apr 25, 2018 7:00am EDT

Aptose to Present at the Bloom Burton & Co. Healthcare Investor Conference 2018

Apr 24, 2018 7:00am EDT

Aptose Presents Preclinical Data on APTO-253 at 2018 AACR Annual Meeting

Apr 17, 2018 2:00pm EDT
RSS
  • Prev
    • 1...
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • ...20
    Next
    © 2021 Aptose Biosciences Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap